Functional polymorphisms in UDP-glucuronosyl transferases and recurrence in tamoxifen-treated breast cancer survivors

Cancer Epidemiology Biomarkers and Prevention

Volumn 20, Issue 9, 2011, Pages 1937-1943

  Ahern, Thomas P ^a,b   Christensen, Mariann ^c   Cronin Fenton, Deirdre P ^c   Lunetta, Kathryn L ^b   Siøland, Hav̊ard ^d   Gjerde, Jennifer ^e   Garne, Jens Peter ^c   Rosenberg, Carol L ^b   Silliman, Rebecca A ^b   Srøensen, Henrik Toft ^c   Lash, Timothy L ^b,c   Hamilton Dutoit, Stephen ^c  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c AALBORG UNIVERSITY HOSPITAL   (Denmark)

^d STAVANGER UNIVERSITY HOSPITAL   (Norway)

^e HAUKELAND UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2D6; ESTROGEN RECEPTOR; GLUCURONOSYLTRANSFERASE; GLUCURONOSYLTRANSFERASE 1A8; GLUCURONOSYLTRANSFERASE 2B15; GLUCURONOSYLTRANSFERASE 2B7; TAMOXIFEN; UNCLASSIFIED DRUG;

ADULT; AGED; ALLELE; ARTICLE; BREAST CANCER; CANCER PATIENT; CANCER RECURRENCE; CANCER REGISTRY; CANCER STAGING; CANCER SURVIVOR; CONTROLLED STUDY; DEMOGRAPHY; FEMALE; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MENOPAUSE; PRIMARY TUMOR; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; AGED; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; FEMALE; GENOTYPE; GLUCURONOSYLTRANSFERASE; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; POLYMORPHISM, GENETIC; TAMOXIFEN;

EID: 80052551518     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-11-0419     Document Type: Article

References (19)

1. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet 2005;365:1687-1717
2. Borges S., Desta Z., Li L., Skaar T.C., Ward B.A., Nguyen A., et al. Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: Implication for optimization of breast cancer treatment. Clin Pharmacol Ther 2006;80:61-74. (Pubitemid 43946844)
3. Lim Y.C., Desta Z., Flockhart D.A., Skaar T.C. Endoxifen (4-hydroxy-N-desmethyl- tamoxifen) has anti-estrogenic effects in breast cancer cells with potency similar to 4-hydroxy-tamoxifen. Cancer Chemother Pharmacol 2005;55:471-478 (Pubitemid 40568978)
4. Lazarus P., Blevins-Primeau A.S., Zheng Y., Sun D. Potential role of UGT pharmacogenetics in cancer treatment and prevention: Focus on tamoxifen. Ann N Y Acad Sci 2009;1155:99-111.
5. Nishiyama T., Ogura K., Nakano H., Ohnuma T., Kaku T., Hiratsuka A., et al. Reverse geometrical selectivity in glucuronidation and sulfation of cis- and trans-4-hydroxytamoxifens by human liver UDP-glucuronosyltransferases and sulfotransferases. Biochem Pharmacol 2002;63:1817-1830 (Pubitemid 34603446)
6. Zheng Y., Sun D., Sharma A.K., Chen G., Amin S., Lazarus P. Elimination of antiestrogenic effects of active tamoxifen metabolites by glucuronidation. Drug Metab Dispos 2007;35:1942-1948 (Pubitemid 47481590)
7. Sun D., Sharma A.K., Dellinger R.W., Blevins-Primeau A.S., Balliet R.M., Chen G., et al. Glucuronidation of active tamoxifen metabolites by the human UDP glucuronosyltransferases. Drug Metab Dispos 2007;35:2006-2014 (Pubitemid 350010805)
8. Levesque E., Beaulieu M., Green M.D., Tephly T.R., Belanger A., Hum D.W. Isolation and characterization of UGT2B15(Y85): A UDP-glucuronosyltransferase encoded by a polymorphic gene. Pharmacogenetics 1997;7:317-325 (Pubitemid 27356932)
9. Levesque E., Delage R., Benoit-Biancamano M.O., Caron P., Bernard O., Couture F., et al. The impact of UGT1A8, UGT1A9, and UGT2B7 genetic polymorphisms on the pharmacokinetic profile of mycophenolic acid after a single oral dose in healthy volunteers. Clin Pharmacol Ther 2007;81:392-400. (Pubitemid 46364482)
10. Blevins-Primeau A.S., Sun D., Chen G., Sharma A.K., Gallagher C.J., Amin S., et al. Functional significance of UDP-glucuronosyltransferase variants in the metabolism of active tamoxifen metabolites. Cancer Res 2009;69:1892-1900
11. Lash T.L., Cronin-Fenton D., Ahern T.P., Rosenberg C.L., Lunetta K.L., Silliman R.A., et al. CYP2D6 inhibition and breast cancer recurrence in a population-based study in Denmark. J Natl Cancer Inst 2011;103: 489-500.
12. Cronin-Fenton D., Lash T.L. Clinical epidemiology and pharmacology of CYP2D6 inhibition related to breast cancer outcomes. Expert Rev Clin Pharmacol 2011;4:363-377
13. Nowell S.A., Ahn J., Rae J.M., Scheys J.O., Trovato A., Sweeney C., et al. Association of genetic variation in tamoxifen-metabolizing enzymes with overall survival and recurrence of disease in breast cancer patients. Breast Cancer Res Treat 2005;91: 249-258 (Pubitemid 40903087)
14. Wegman P., Elingarami S., Carstensen J., Stal O., Nordenskjold B., Wingren S. Genetic variants of CYP3A5, CYP2D6, SULT1A1, UGT2B15 and tamoxifen response in postmenopausal patients with breast cancer. Breast Cancer Res 2007;9:R7.
15. Blichert-Toft M., Christiansen P., Mouridsen H.T. Danish Breast Cancer Cooperative Group-DBCG: History, organization, and status of scientific achievements at 30-year anniversary. Acta Oncol 2008;47: 497-505. (Pubitemid 351878432)
16. Moller S., Jensen M.B., Ejlertsen B., Bjerre K.D., Larsen M., Hansen H.B., et al. The clinical database and the treatment guidelines of the Danish Breast Cancer Cooperative Group (DBCG); its 30-years experience and future promise. Acta Oncol 2008;47:506-524 (Pubitemid 351878431)
17. Albert C., Vallee M., Beaudry G., Belanger A., Hum D.W. The monkey and human uridine diphosphate-glucuronosyltransferase UGT1A9, expressed in steroid target tissues, are estrogen-conjugating enzymes. Endocrinology 1999;140:3292-3302 (Pubitemid 30650648)
18. Yong M., Schwartz S.M., Atkinson C., Makar K.W., Thomas S.S., Stanczyk F.Z., et al. Associations between polymorphisms in glucuronidation and sulfation enzymes and sex steroid concentrations in premenopausal women in the United States. J Steroid Biochem Mol Biol 2011;124:10-18
19. Lash T.L., Lien E.A., Sorensen H.T., Hamilton-Dutoit S. Genotype-guided tamoxifen therapy: Time to pause for reflection?Lancet Oncol 2009;10:825-833